Corporate History
April 2001 |
Founded in Shiba, Minato-ku, Tokyo to contribute to research and development of anti-cancer medicine, cancer therapy and cancer diagnosis based on oncogenes and proteins. |
May 2001 |
Commenced collaboration with the Institute of Medical Science, University of Tokyo. |
November 2001 |
Head office moved to Shiroganedai, Minato-ku, Tokyo. |
October 2002 |
Opened research laboratory at the same place as head office in Minato-ku, Tokyo. |
December 2003 |
Listed on the Tokyo Securities Exchange Mothers Index. |
March 2005 |
Head office and head office laboratory facilities moved to Takatsu-ku, Kawasaki city, Kanagawa prefecture, and opened Drug Discovery Laboratory at the same address. |
June 2006 |
Founded Vaccine Science Inc., consolidated subsidiary company of OTS, to develop peptide vaccines. |
September 2007 |
Associated company Immunas Pharma, Inc. becomes a consolidated subsidiary of OTS through its stock acquisition. |
September 2007 |
Merged with consolidated subsidiary company Vaccine Science Inc. |
May 2010 |
Established Laboratoires OncoTherapy Science France S.A.R.L., a consolidated subsidiary, to contribute in research and development of anti-cancer medicine such as antibody medicine in France. |
July 2017 |
Established Cancer Precision Medicine, Inc., a consolidated subsidiary which will conduct the genome analysis of cancer, liquid biopsy, and development of new immunotherapy including the neoantigen prediction. |
August 2017 |
Cancer Precision Medicine, Inc. changed a corporate joint venture with OncoTherapy Science, Inc. and Theragen Etex Co., Ltd.. |
October 2017 |
Company Split Tumor Immunology Dept. from OncoTherapy Science, to Cancer Precision Medicine, Inc. |
December 2017 |
Opened Clinical Lab. of Cancer Precision Medicine, Inc.. |